WO2023047291A1 - Aerosol comprising ethanol 60 and 90% w/w and a solvent for treating a respiratory infection - Google Patents

Aerosol comprising ethanol 60 and 90% w/w and a solvent for treating a respiratory infection Download PDF

Info

Publication number
WO2023047291A1
WO2023047291A1 PCT/IB2022/058908 IB2022058908W WO2023047291A1 WO 2023047291 A1 WO2023047291 A1 WO 2023047291A1 IB 2022058908 W IB2022058908 W IB 2022058908W WO 2023047291 A1 WO2023047291 A1 WO 2023047291A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
use according
virus
respiratory
cov
Prior art date
Application number
PCT/IB2022/058908
Other languages
French (fr)
Inventor
Alberto Patarchi
Original Assignee
Alberto Patarchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alberto Patarchi filed Critical Alberto Patarchi
Publication of WO2023047291A1 publication Critical patent/WO2023047291A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to a composition for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.
  • Some vaccines have been produced using the same technology (or “platform”) as vaccines currently in use, others are produced using new approaches or approaches used in the development of vaccines against SARS and Ebola.
  • the objective of all these vaccines is to produce an immune response with the aim of neutralising the virus and preventing the infection of cells.
  • the main platforms used are the following: inactivated virus vaccines, live attenuated virus vaccines, recombinant protein vaccines, viral vector vaccines, DNA vaccines and RNA vaccines.
  • the vaccines are very effective in avoiding the severe symptoms of COVID-19 and in reducing the possibility of contagion to a minimum, but they are not a therapy for the disease.
  • numerous antiviral molecules that can be used in therapy against COVID-19 are also under study, including, for example, monoclonal antibodies or specific antiviral drugs against SARS-CoV-2.
  • hypochlorous acid-based nasal spray eliminates Sars-Cov-2 in less than a minute without irritating the mucosa of the nose and throat.
  • a first aspect of the present invention relates to a composition
  • a composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w and at least one solvent for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.
  • the respiratory-transmissible pathogen is selected from: an influenza virus, a parainfluenza virus, respiratory syncytial virus, a rhinovirus, a virus of the family Coronaviridae, an adenovirus and a mycobacterium.
  • the respiratory- transmissible pathogen is a virus of the family Coronaviridae, more preferably selected from SARS-CoV, MERS-CoV and SARS-CoV-2; even more preferably it is SARS-CoV-2.
  • a second aspect of the present invention relates to a method for preventing a viral infection or disease caused by a respiratory- transmissible pathogen in an individual, preferably a virus belonging to the family Coronaviridae.
  • the virus is selected from: SARS-CoV, MERS-CoV and SARS-CoV-2.
  • the virus is SARS- CoV-2.
  • the method comprises at least one step of administering the composition described above in detail to an individual.
  • ethyl alcohol or “ethanol” means an alcohol with the formula CH3-CH2-OH.
  • the term “respiratory virus” means a virus that is inhaled and transmitted through the respiratory tract.
  • Coronaviridae means a large family of respiratory viruses that can cause mild to moderate illnesses, which range from the common cold to respiratory syndromes such as ME RS (Middle East respiratory syndrome) and SARS (severe acute respiratory syndrome), as well as other viruses responsible for pathologies, not only respiratory ones, in human beings and in domestic and wild animals.
  • ME RS Middle East respiratory syndrome
  • SARS severe acute respiratory syndrome
  • infection means a process characterised by the penetration and multiplication of viruses in living tissues.
  • the concept of infection is not identifiable with that of infectious disease or pathology, as there exist cases of infection without any morbid phenomenon, i.e. asymptomatic individuals who are carriers of the pathogen.
  • a first aspect of the present invention relates to a composition
  • a composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w and at least one solvent for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.
  • the composition is administered by aerosol, i.e. the composition is nebulised and is administered in the form of microparticles.
  • said microparticles haven a size of between 0.3 and 5 pm.
  • the particles have an average size of less than 2 pm.
  • the respiratory-transmissible pathogen is selected from: an influenza virus, a parainfluenza virus, respiratory syncytial virus, a rhinovirus, a virus of the family Coronaviridae, an adenovirus and a mycobacterium.
  • the respiratory-transmissible pathogen is preferably a virus of the family Coronaviridae, more preferably selected from SARS-CoV, MERS-CoV and SARS-CoV-2; even more preferably it is SARS-CoV-2.
  • the disease caused by a respiratory-transmissible pathogen is an infectious disease, an acute respiratory disease, or a disease of a systemic type, or an asymptomatic or paucisymptomatic infection preferably caused by the SARS-CoV-2 virus, known as COVID- 19.
  • the ethyl alcohol concentration of the composition is between 60 and 90 % w/w, even more preferably between 70 and 80% w/w.
  • the ethyl alcohol concentration in the composition is 74-75% w/w.
  • the solvent is preferably water or ozonised water, more preferably sterile water.
  • the composition also comprises at least one flavouring agent, preferably chosen from: vanilla, mint, tobacco, lavender, coffee, lemon, orange, pistachio, cocoa, hazelnut, almond, grape, melon, berry, coconut, kiwi, and combinations thereof.
  • at least one flavouring agent preferably chosen from: vanilla, mint, tobacco, lavender, coffee, lemon, orange, pistachio, cocoa, hazelnut, almond, grape, melon, berry, coconut, kiwi, and combinations thereof.
  • composition of the present invention is taken both by an individual with a blood oxygen saturation within the normal limits, and by an individual with a blood oxygen saturation below the normal limits.
  • the individual has a normal blood oxygen saturation, i.e. higher than 92%, preferably higher than 95%.
  • the composition is preferably taken at least once a day, more preferably at least twice a day, by an individual with a normal blood oxygen saturation.
  • the individual has a blood oxygen saturation that is lower than normal, i.e. between 70 and 80%.
  • the composition is preferably taken at least twice a day, more preferably at least three times a day by an individual with a blood oxygen saturation that is lower than normal.
  • the individual has a blood oxygen saturation that is much lower than normal, lower than 70%, more preferably lower than 65%.
  • the composition is preferably taken at least three times a day, more preferably at least four times a day by an individual with a blood oxygen saturation that is much lower than normal.
  • composition of the present invention is taken in association or in combination with at least one antiviral drug and/or an anti-inflammatory drug and/or an antipyretic drug and/or an antibiotic.
  • the Applicant has surprisingly discovered that, by administering the composition of the present invention in the form of microparticles, one obtains the complete destruction of a virus in the respiratory tract.
  • a virus in particular a respiratory virus, such as, for example, SARS-CoV-2.
  • composition of the present invention can be administered using an atomiser or vaporiser which, thanks also to the use of ultrasound and/or heat, is capable of generating microparticles with a size of between 0.3 and 5 pm.
  • a second aspect of the present invention relates to a method for preventing a viral infection or a disease caused by a virus, preferably by a virus belonging to the family of the Coronaviridae.
  • the virus is selected from: SARS-CoV, MERS-CoV and SARS-CoV-2.
  • the virus is SARS-CoV-2.
  • the disease caused by a respiratory-transmissible pathogen is an infectious disease, an acute respiratory disease, or a disease of a systemic type, or an asymptomatic or paucisymptomatic infection preferably caused by the SARS-CoV-2 virus, known as COVID- 19.
  • the method comprises at least one step of administering the composition described above in detail to an individual.
  • the individual has a normal blood oxygen saturation, i.e. higher than 92%, preferably higher than 95%.
  • the composition is preferably taken at least once a day, more preferably at least twice a day by an individual with a normal blood oxygen saturation.
  • the individual has a blood oxygen saturation that is lower than normal, i.e. between 70 and 80%.
  • the composition is preferably taken at least twice a day, more preferably at least three times a day by an individual with a blood oxygen saturation that is lower than normal.
  • the individual has a blood oxygen saturation that is much lower than normal, lower than 70%, more preferably lower than 65%.
  • the composition is preferably taken at least three times a day, more preferably at least four times a day by an individual with a blood oxygen saturation that is much lower than normal.
  • composition of the present invention is taken in association or in combination with at least one antiviral drug and/or an anti-inflammatory drug and/or an antipyretic drug and/or an antibiotic.
  • a third aspect of the present invention relates to a kit comprising an atomiser and at least one composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w, as described in detail above.

Abstract

The present invention relates to a composition comprising ethyl alcohol for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.

Description

TITLE
AEROSOL COMPRISING ETHANOL 60 AND 90% W/W AND A SOLVENT FOR TREATING A RESPIRATORY INFECTION
DESCRIPTION
Technical field
The present invention relates to a composition for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.
Prior art
Since the genetic sequence of the SARS-CoV-2D virus was published on 11 January 2020, scientists, industries and other organisations all over the world have worked together to develop safe, effective vaccines against COVID-19 as quickly as possible.
According to the overview of the World Health Organization (WHO), as of 22 January 2021 , there were 237 candidate vaccines undergoing development, 173 of which in a pre-clinical phase and 64 in a clinical phase (16 of the latter in phase 3).
Some vaccines have been produced using the same technology (or “platform”) as vaccines currently in use, others are produced using new approaches or approaches used in the development of vaccines against SARS and Ebola. The objective of all these vaccines is to produce an immune response with the aim of neutralising the virus and preventing the infection of cells. The main platforms used are the following: inactivated virus vaccines, live attenuated virus vaccines, recombinant protein vaccines, viral vector vaccines, DNA vaccines and RNA vaccines.
In any case, the vaccines are very effective in avoiding the severe symptoms of COVID-19 and in reducing the possibility of contagion to a minimum, but they are not a therapy for the disease. In fact, numerous antiviral molecules that can be used in therapy against COVID-19 are also under study, including, for example, monoclonal antibodies or specific antiviral drugs against SARS-CoV-2.
Moreover, other strategies are being developed to stop the pandemic. For example, in Italy experimentation has begun on a nasal spray to be applied in patients with early symptoms of COVID-19. The spray is an aqueous washing solution that contains 0.005% hypochlorous acid, an antimicrobial substance also produced by the cells of our immune system, rendered stable and pure. The recently published results of preliminary in vitro and in vivo tests have demonstrated that hypochlorous acid-based nasal spray eliminates Sars-Cov-2 in less than a minute without irritating the mucosa of the nose and throat.
Thus, there is still a greatly felt need to develop new drugs and/or new strategies for the prevention and treatment of COVID-19 disease.
Summary of the invention
A first aspect of the present invention relates to a composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w and at least one solvent for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.
In one embodiment of the invention, the respiratory-transmissible pathogen is selected from: an influenza virus, a parainfluenza virus, respiratory syncytial virus, a rhinovirus, a virus of the family Coronaviridae, an adenovirus and a mycobacterium. Preferably, the respiratory- transmissible pathogen is a virus of the family Coronaviridae, more preferably selected from SARS-CoV, MERS-CoV and SARS-CoV-2; even more preferably it is SARS-CoV-2.
A second aspect of the present invention relates to a method for preventing a viral infection or disease caused by a respiratory- transmissible pathogen in an individual, preferably a virus belonging to the family Coronaviridae. In one embodiment the virus is selected from: SARS-CoV, MERS-CoV and SARS-CoV-2. Preferably, the virus is SARS- CoV-2.
The method comprises at least one step of administering the composition described above in detail to an individual.
Definitions
In the context of the present invention, the term “ethyl alcohol” or “ethanol” means an alcohol with the formula CH3-CH2-OH.
In the context of the present invention, the term “respiratory virus” means a virus that is inhaled and transmitted through the respiratory tract.
In the context of the present invention, the term Coronaviridae (abbreviated as “CoV”) means a large family of respiratory viruses that can cause mild to moderate illnesses, which range from the common cold to respiratory syndromes such as ME RS (Middle East respiratory syndrome) and SARS (severe acute respiratory syndrome), as well as other viruses responsible for pathologies, not only respiratory ones, in human beings and in domestic and wild animals.
In the context of the present invention, the term “infection” means a process characterised by the penetration and multiplication of viruses in living tissues. The concept of infection is not identifiable with that of infectious disease or pathology, as there exist cases of infection without any morbid phenomenon, i.e. asymptomatic individuals who are carriers of the pathogen.
Detailed description of preferred embodiments of the invention
A first aspect of the present invention relates to a composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w and at least one solvent for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual.
In one embodiment, the composition is administered by aerosol, i.e. the composition is nebulised and is administered in the form of microparticles. Preferably, said microparticles haven a size of between 0.3 and 5 pm. In a preferred embodiment of the invention, the particles have an average size of less than 2 pm.
In one embodiment of the invention, the respiratory-transmissible pathogen is selected from: an influenza virus, a parainfluenza virus, respiratory syncytial virus, a rhinovirus, a virus of the family Coronaviridae, an adenovirus and a mycobacterium. The respiratory-transmissible pathogen is preferably a virus of the family Coronaviridae, more preferably selected from SARS-CoV, MERS-CoV and SARS-CoV-2; even more preferably it is SARS-CoV-2.
In one embodiment, the disease caused by a respiratory-transmissible pathogen is an infectious disease, an acute respiratory disease, or a disease of a systemic type, or an asymptomatic or paucisymptomatic infection preferably caused by the SARS-CoV-2 virus, known as COVID- 19.
Preferably, the ethyl alcohol concentration of the composition is between 60 and 90 % w/w, even more preferably between 70 and 80% w/w.
In a preferred embodiment of the invention, the ethyl alcohol concentration in the composition is 74-75% w/w.
In one embodiment, the solvent is preferably water or ozonised water, more preferably sterile water.
In a further embodiment, the composition also comprises at least one flavouring agent, preferably chosen from: vanilla, mint, tobacco, lavender, coffee, lemon, orange, pistachio, cocoa, hazelnut, almond, grape, melon, berry, coconut, kiwi, and combinations thereof.
The composition of the present invention is taken both by an individual with a blood oxygen saturation within the normal limits, and by an individual with a blood oxygen saturation below the normal limits.
In one embodiment, the individual has a normal blood oxygen saturation, i.e. higher than 92%, preferably higher than 95%. The composition is preferably taken at least once a day, more preferably at least twice a day, by an individual with a normal blood oxygen saturation.
In one embodiment, the individual has a blood oxygen saturation that is lower than normal, i.e. between 70 and 80%. The composition is preferably taken at least twice a day, more preferably at least three times a day by an individual with a blood oxygen saturation that is lower than normal.
In one embodiment, the individual has a blood oxygen saturation that is much lower than normal, lower than 70%, more preferably lower than 65%. The composition is preferably taken at least three times a day, more preferably at least four times a day by an individual with a blood oxygen saturation that is much lower than normal.
In one embodiment, the composition of the present invention is taken in association or in combination with at least one antiviral drug and/or an anti-inflammatory drug and/or an antipyretic drug and/or an antibiotic.
The Applicant has surprisingly discovered that, by administering the composition of the present invention in the form of microparticles, one obtains the complete destruction of a virus in the respiratory tract. In particular, thanks to the administration by aerosol of microparticles with a size of between 0.3 and 5 pm, it is possible to reach the lower respiratory tract, i.e. the lung alveoli, where a virus can settle. The administration of the composition by aerosol is capable of destroying a virus, in particular a respiratory virus, such as, for example, SARS-CoV-2.
The composition of the present invention can be administered using an atomiser or vaporiser which, thanks also to the use of ultrasound and/or heat, is capable of generating microparticles with a size of between 0.3 and 5 pm.
Kinetic studies on aerosols have in fact demonstrated that particles with a diameter of between 0.3 and 5 pm are capable of reaching the respiratory tract with a lung alveolus diameter of less than 2 mm.
A second aspect of the present invention relates to a method for preventing a viral infection or a disease caused by a virus, preferably by a virus belonging to the family of the Coronaviridae. In one embodiment the virus is selected from: SARS-CoV, MERS-CoV and SARS-CoV-2. Preferably, the virus is SARS-CoV-2.
In one embodiment, the disease caused by a respiratory-transmissible pathogen is an infectious disease, an acute respiratory disease, or a disease of a systemic type, or an asymptomatic or paucisymptomatic infection preferably caused by the SARS-CoV-2 virus, known as COVID- 19.
The method comprises at least one step of administering the composition described above in detail to an individual.
In one embodiment, the individual has a normal blood oxygen saturation, i.e. higher than 92%, preferably higher than 95%. The composition is preferably taken at least once a day, more preferably at least twice a day by an individual with a normal blood oxygen saturation.
In one embodiment, the individual has a blood oxygen saturation that is lower than normal, i.e. between 70 and 80%. The composition is preferably taken at least twice a day, more preferably at least three times a day by an individual with a blood oxygen saturation that is lower than normal.
In one embodiment, the individual has a blood oxygen saturation that is much lower than normal, lower than 70%, more preferably lower than 65%. The composition is preferably taken at least three times a day, more preferably at least four times a day by an individual with a blood oxygen saturation that is much lower than normal.
In one embodiment, the composition of the present invention is taken in association or in combination with at least one antiviral drug and/or an anti-inflammatory drug and/or an antipyretic drug and/or an antibiotic.
A third aspect of the present invention relates to a kit comprising an atomiser and at least one composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w, as described in detail above.

Claims

7 CLAIMS
1 . A composition comprising ethyl alcohol in a concentration of between 60 and 90% w/w and at least one solvent for use in the treatment or prevention of an infection or disease caused by a respiratory-transmissible pathogen in an individual, wherein the composition is administered by aerosol in the form of microparticles having a size of between 0.3 and 5 pm, wherein the solvent is ozonised water.
2. The composition for use according to claim 1 , wherein the respiratory- transmissible pathogen is selected from: an influenza virus, a parainfluenza virus, respiratory syncytial virus, a rhinovirus, a virus of the family Coronaviridae, an adenovirus and a mycobacterium.
3. The composition for use according to claim 2, wherein the respiratory- transmissible pathogen is a virus of the family Coronaviridae.
4. The composition for use according to claim 3, wherein the virus of the family Coronaviridae is selected from SARS-CoV, MERS-CoV and SARS- CoV-2.
5. The composition for use according to claim 4, wherein the virus is SARS-CoV-2.
6. The composition for use according to any one of claims 1 -5, wherein the microparticles have an average size of less than 2 pm.
7. The composition for use according to any one of claims 1 -6, wherein the ethyl alcohol concentration is between 70 and 80% w/w, preferably it is 74- 75% w/w.
8. The composition for use according to any one of claims 1 -7, wherein the 8 individual has a blood oxygen saturation higher than 92%.
9. The composition for use according to any one of claims 1 -8, wherein the composition is taken at least twice a day.
10. The composition for use according to any one of claims 1 -7, wherein the individual has a blood oxygen saturation of between 70 and 80%.
11. The composition for use according to any one of claims 1 -7 or 10, wherein the composition is taken at least three times a day.
12. The composition for use according to any one of claims 1 -7, wherein the individual has a blood oxygen saturation lower than 70%.
13. The composition for use according to any one of claims 1 -7 or 12, wherein the composition is taken at least four times a day.
14. The composition for use according to any one of claims 1 -13, taken in association or in combination with at least one antiviral drug and/or an anti-inflammatory drug and/or an antipyretic drug and/or an antibiotic.
15. The composition for use according to any one of claims 1 -14, wherein the composition comprises at least one flavouring agent, preferably chosen from: vanilla, mint, tobacco, lavender, coffee, lemon, orange, pistachio, cocoa, hazelnut, almond, grape, melon, berry, coconut, kiwi, and combinations thereof.
PCT/IB2022/058908 2021-09-21 2022-09-21 Aerosol comprising ethanol 60 and 90% w/w and a solvent for treating a respiratory infection WO2023047291A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000024146 2021-09-21
IT102021000024146A IT202100024146A1 (en) 2021-09-21 2021-09-21 New medical use of a composition

Publications (1)

Publication Number Publication Date
WO2023047291A1 true WO2023047291A1 (en) 2023-03-30

Family

ID=79019166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/058908 WO2023047291A1 (en) 2021-09-21 2022-09-21 Aerosol comprising ethanol 60 and 90% w/w and a solvent for treating a respiratory infection

Country Status (2)

Country Link
IT (1) IT202100024146A1 (en)
WO (1) WO2023047291A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200268656A1 (en) * 2020-05-14 2020-08-27 Darren Rubin Nebulized Ethanol for Internal Disinfecting and Improvement
RU2740273C1 (en) * 2020-06-10 2021-01-12 Валерий Викторович Педдер Individual device for protection of respiratory organs from infection
WO2021229550A1 (en) * 2020-05-15 2021-11-18 Sandro Pazzaglia Hydroalcoholic composition for the reduction of the viral activity
US20210369719A1 (en) * 2020-05-26 2021-12-02 Binyomin A. Cohen Accelerated Treatment of COVID-19 and SAR's Type Viruses
WO2022047538A1 (en) * 2020-09-03 2022-03-10 Telethon Kids Institute System and method for delivery of a therapeutic agent by inhalation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200268656A1 (en) * 2020-05-14 2020-08-27 Darren Rubin Nebulized Ethanol for Internal Disinfecting and Improvement
WO2021229550A1 (en) * 2020-05-15 2021-11-18 Sandro Pazzaglia Hydroalcoholic composition for the reduction of the viral activity
US20210369719A1 (en) * 2020-05-26 2021-12-02 Binyomin A. Cohen Accelerated Treatment of COVID-19 and SAR's Type Viruses
RU2740273C1 (en) * 2020-06-10 2021-01-12 Валерий Викторович Педдер Individual device for protection of respiratory organs from infection
WO2022047538A1 (en) * 2020-09-03 2022-03-10 Telethon Kids Institute System and method for delivery of a therapeutic agent by inhalation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MISHRA MADHUSMITA ET AL: "Formulation optimization and characterization of spray dried microparticles for inhalation delivery of doxycycline hyclate.", YAKUGAKU ZASSHI : JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 2011, vol. 131, no. 12, 2011, pages 1813 - 1825, XP009535523, ISSN: 1347-5231 *

Also Published As

Publication number Publication date
IT202100024146A1 (en) 2023-03-21

Similar Documents

Publication Publication Date Title
US20130060235A1 (en) Pharmaceutical compositions and methods of use
US20110020279A1 (en) Rabies cure
US11801271B2 (en) Stable bacterial extracts as pharmaceuticals
CN103687599A (en) The use of chloroquine, chlorpromazine, derivatives thereof, or mixtures thereof in preparing medications for treating and/or preventing pulmonary infection and injury
US20090169487A1 (en) Essential Oil Diffusion
WO2010064061A1 (en) Pharmaceutical compositions and methods of sinonasal delivering the same
KR20170033925A (en) Spray compositions having antiviral efficacy and antibacterial agent
CN112791097A (en) Application of iodine in preparing medicament for preventing and treating respiratory infectious diseases and method for preparing low-particle-size iodine-containing aerosol
WO2023047291A1 (en) Aerosol comprising ethanol 60 and 90% w/w and a solvent for treating a respiratory infection
Zakir et al. Khamira Banafsha for the symptomatic treatment of Covid-19 Disease
WO2022063320A1 (en) Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method
Ezz et al. Disinfection of SARS-COV-2 (COVID-19) in human respiratory tract by controlled ethanol vapor inhalation combined with Asprin
JP2012193159A (en) Nasal spray
Becker Essential Oils and Coronaviruses
Geppe et al. New methods of prevention and treatment of acute respiratory viral infections in children. Local protection factors of the respiratory mucosa
JP2010189301A (en) Pharmaceutical composition effective against novel influenza and use thereof
US20220273594A1 (en) Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections
RU2735502C1 (en) Aerosol for inhalations in obstructive bronchitis
Altaei et al. Topical treatment of herpes simplex lesion by lavender cream
US11179415B1 (en) Process of using chlorine dioxide for the attenuation and/or treatment of Coronavirus diseases such as COVID-19 and disabling, treating or attenuating the SARS CoV-2 virus, and its future infective variants
Gonzalez Iodine Oral and Nasal Rinsing: A Potential Therapeutic for COVID-19
Sarhan et al. Virucidal activity of oriental hornet Vespa orientalis venom against hepatitis C virus
Jangir et al. MODERN THERAPEUTICS, VACCINES AND FUTURE CHALLENGES IN THE TREATMENT OF COVID-19
US20220096407A1 (en) Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method
RU2773149C2 (en) Compositions and methods for protection against pathogens and irritants present in air

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22790361

Country of ref document: EP

Kind code of ref document: A1